To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Cat. No.: TDLD-0825-LD107
Esbp Pep-LNP
Esbp Pep-LNP is a state-of-the-art peptide-functionalized lipid nanoparticle (LNP), designed for efficient targeted delivery of therapeutic cargoes such as siRNA, mRNA, DNA, small molecule drugs, and RNA-guided gene editing systems. Engineered with the Esbp peptide, this LNP exhibits high affinity for E-selectin, which is highly expressed on the surface of endothelial cells at sites of inflammation, metastatic tumors, and leukemia, enabling active targeted delivery. Our LNP is prepared using Targeting Module and a variety of optional lipid formulations including DLin-MC3-DMA, LP-01, ALC-0315, SM102, and others. These formulations are carefully selected to ensure the LNP has uniform particle size, high encapsulation efficiency, stability, and targeted delivery. Applications of Esbp Pep-LNP include developing targeted therapeutics and imaging agents for inflammatory diseases, metastatic cancers, and hematological malignancies, studying E-selectin biology and its role in disease progression, and evaluating novel strategies for enhancing tissue penetration and cellular uptake efficiency at specific pathological sites. Please note that this product is intended for research purposes only.
Inquiry
SPECIFIC INQUIRY
Clear AllInquiry
For Research Use Only. Not for Diagnostic or Treatment Applications.
Creatibe Biolabs' custom LNP was the only solution that
successfully delivered our CRISPR-Cas9 payload across the blood-brain barrier with high
efficiency and low toxicity.”
Dr. Evelyn Reed
Postdoctoral Researcher, Leading
University
Our siRNA candidate was failing due to off-target toxicity, but
Creatibe Biolabs' team rapidly redesigned our LNP using their modular platform, rescuing our
preclinical program.”
Ben Carter
Project Manager
Achieving cytosolic delivery of our protein degrader with Creatibe Biolabs' exosome platform
was the key to unlocking our candidate's full therapeutic potential.”
Dr. Kenji Tanaka
Principal Scientist, Large
Pharma Corp
Our oncology drug's efficacy was limited by poor tumor
accumulation. Creatibe Biolabs' peptide-conjugated liposomes provided the precise targeting
we needed, dramatically increasing the drug's therapeutic index.”
Dr. Clara Schmidt
Senior Scientist, Oncology
Innovations Inc.
We required a delivery system that would only release its payload
in the tumor's acidic microenvironment. Creatibe Biolabs' pH-responsive liposomes performed
flawlessly, minimizing systemic exposure.”
David Chen
Formulation Scientist
Outstanding expertise in antibody engineering.The team's attention
to detail and innovative approaches have sianificantly accelerated our development timeline.
